問卷

TPIDB > Principal Investigator

Principal Investigator


Taipei Veterans General Hospital (在職)

Division of Urology

更新時間:2023-09-19

黃志賢Huang, William
  • Principal Investigator
  • Clinical Trial Experience (year) -23 years -4 個月

篩選

List

39Cases

2025-08-01 - 2035-08-31

Phase III

Active
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
6Sites

Recruiting6Sites

2025-04-01 - 2027-12-31

Phase III

Active
A phase 3, two-part, randomized, open-label, modified trial comparing BMS-986365 with a trial-administered therapy (including Docetaxel or a second androgen receptor pathway inhibitor [ARPI]) in participants with metastatic castration-resistant prostate cancer (mCRPC) - rechARge
  • Condition/Disease

    Metastatic castration-resistant prostate cancer (mCRPC)

  • Test Drug

    BMS-986365 (CC-94676)

Participate Sites
4Sites

Recruiting4Sites

2021-01-04 - 2026-04-30

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting1Sites

Terminated2Sites

2019-01-01 - 2027-05-27

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Recruiting9Sites

2023-03-20 - 2030-06-30

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2020-10-26 - 2028-06-30

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Not yet recruiting3Sites

Recruiting5Sites

2020-06-01 - 2027-11-06

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Recruiting8Sites

2026-06-01 - 2030-12-31

Phase III

Not yet recruiting
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2022-02-01 - 2026-03-30

Phase I/II

Active
  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2022-05-20 - 2028-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

1 2 3 4